ey are marketed to consumers. The FDA moved to ban Ephedra in the US in 2004. However, the recent headlines about voluntary drug withdrawals have produced questions as to theOn Sept. 30, 2004 Merck announced a worldwide withdrawal of Vioxx® (rofecoxib). Vioxx had previously been prescribed in the treatment of arthritis and pain. Worldwide sales of Vioxx in 2003 were an estimated $2.5Billion and the drug was marketed in more than 80 countries around the world. This is one of several recent pharmaceutical products to have been put in the spotlight by both the national media and plaintiff lawyers.

Since sometime in the mid to late 90s a substantial number of pharmaceutical medications and medical devices have been removed from the market due to possible adverse health implications. The FDA acts as a regulatory body in approving health related products before they are marketed to consumers. The FDA moved to ban Ephedra in the US in 2004. However, the recent headlines about voluntary drug withdrawals have produced questions as to the

Vioxx in 2003 were an estimated $2.5Billion and the drug was marketed in more than 80 countries around the world. This is one of several recent pharmaceutical products to have been put in the spotlight by both the national media and plaintiff lawyers.

Since sometime in the mid to late 90s a substantial number of pharmaceutical medications and medical devices have been removed from the market due to possible adverse health implications. The FDA acts as a regulatory body in approving health related products before they are marketed to consumers. The FDA moved to ban Ephedra in the US in 2004. However, the recent headlines about voluntary drug withdrawals have produced questions as to the

e been put in the spotlight by both the national media and plaintiff lawyers.

Since sometime in the mid to late 90s a substantial number of pharmaceutical medications and medical devices have been removed from the market due to possible adverse health implications. The FDA acts as a regulatory body in approving health related products before they are marketed to consumers. The FDA moved to ban Ephedra in the US in 2004. However, the recent headlines about voluntary drug withdrawals have produced questions as to the

medical devices have been removed from the market due to possible adverse health implications. The FDA acts as a regulatory body in approving health related products before they are marketed to consumers. The FDA moved to ban Ephedra in the US in 2004. However, the recent headlines about voluntary drug withdrawals have produced questions as to theey are marketed to consumers. The FDA moved to ban Ephedra in the US in 2004. However, the recent headlines about voluntary drug withdrawals have produced questions as to the FDA's recent performance.

Many people believe that the FDA did not test the drugs rigorously enough to determine all the possible health problems that they might cause. People believe that the rise in litigation over these medications was due to the fact that the FDA now allows pharmaceutical companies to “fast track” their products and get them through the process in a year. In fact, Vioxx was only released in 1999.

Some of the latest drugs where concerns have also arose are Bextra, Celebrex and Zyprexa. Litigation over these drugs may commence in the near future. US plaintiff lawyers have begun to put some serious time and research into possible claims that may arise from pharma